AcuCort AB (publ) (XSAT:ACUC)

Market Cap	135.51M
Revenue (ttm)	8.00M
Net Income (ttm)	-24.08M
Shares Out	234.44M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	311,831
Average Volume	263,401
Open	0.5680
Previous Close	0.5650
Day's Range	0.5620 - 0.5800
52-Week Range	0.5000 - 1.2000
Beta	1.19
RSI	50.01
Earnings Date	Nov 28, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.